Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 1

Study in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Occurring After Total Knee Arthroplasty (TKA)

NCT05137314 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to learn about the safety and effects of PLG0206 for treating periprosthetic joint infections (PJI) in conjunction with the DAIR (debridement, antibiotics and implant retention) surgical procedure for patients with periprosthetic joint infections (PJI) after total knee arthroplasty (TKA) .

Conditions Studied

Interventions

  • DRUG PLG0206

Study Locations (12)

Ohio

  • Cleveland Clinic — Cleveland
  • Ohio State University — Columbus

Texas

  • Memorial Hermann Hospital — Houston
  • Michael E. DeBakey VA Medical Center — Houston

California

  • Stanford Hospital — Palo Alto

Florida

  • Gulfcoast Research — Sarasota

Maryland

  • LifeBridge — Baltimore

Massachusetts

  • Brigham & Women's Hospital — Boston

New York

  • NYU Langone Orthopedic Hospital — New York

Pennsylvania

  • Rothman — Philadelphia

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2022-03-31
Est. Completion 2024-03-19
Phase Phase 1

Sponsor

Peptilogics

2 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05137314

The ClinicalTrials.gov registry entry for NCT05137314 describes a study currently listed as completed. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Peptilogics, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Joint Infection appearing as the primary indexed condition, and to 1 intervention — of which PLG0206 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05137314 reports 12 study locations spanning 10 distinct geographic areas — top geographies include Ohio, Texas, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05137314 about?

NCT05137314 is a clinical study titled "Study in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Occurring After Total Knee Arthroplasty (TKA)". The purpose of this study is to learn about the safety and effects of PLG0206 for treating periprosthetic joint infections (PJI) in conjunction with the DAIR (debridement, antibiotics and implant retention) surgical procedure for patients with periprosthetic joint infections (PJI) after total knee a...

What is the current status of trial NCT05137314?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2022-03-31. Estimated completion is 2024-03-19.

What conditions does trial NCT05137314 study?

This clinical trial studies the following conditions: Joint Infection. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05137314?

The interventions under investigation include: PLG0206 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05137314?

This trial is sponsored by Peptilogics, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05137314 being conducted?

This trial has 12 study locations across California, Florida, Maryland, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial